Patient and Physician Preferences for Fixed-Duration Vs Treatment to Progression Chronic Lymphocytic Leukemia (CLL) Treatments: Results from a Multi-Country Discrete Choice Experiment

被引：0
|
作者：
Sile, Bersabeh [1 ]
Horchi, Dahbia [2 ]
Rault, Bleuenn [2 ]
Mulvihill, Emily [3 ]
Beusterien, Kathleen [4 ]
Teschemaker, Anna [5 ]
Stewart, Katherine [5 ]
De Miranda, Paulo Andre P. Palhares [5 ]
Guillaume, Xavier [2 ]
机构：
[1] AstraZeneca, Cambridge, England
[2] Oracle Co, Cerner Enviza, Paris, France
[3] Oracle Co, Cerner Enviza, North Kansas City, MO USA
[4] Oracle Co, Real World Evidence, Cerner Enviza, Kansas City, MO USA
[5] AstraZeneca, Gaithersburg, MD USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177690
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 39 条
  • [21] How Do People with Experience of Infertility Value Different Aspects of Assistive Reproductive Therapy? Results from a Multi-Country Discrete Choice Experiment
    Chris Skedgel
    Eleanor Ralphs
    Elaine Finn
    Marie Markert
    Carl Samuelsen
    Jennifer A. Whitty
    The Patient - Patient-Centered Outcomes Research, 2022, 15 : 459 - 472
  • [22] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study
    Burger, J. A.
    Barr, P. M.
    Allan, J. N.
    Siddiqi, T.
    Wierda, W. G.
    Tam, C. S.
    Moreno, C.
    Tedeschi, A.
    Szafer-Glusman, E.
    Zhou, C.
    Abbazio, C.
    Dean, J. P.
    Szoke, A.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 87 - 88
  • [23] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
    Barr, Paul M.
    Allan, John N.
    Siddiqi, Tanya
    Wierda, William G.
    Tam, Constantine Si Lun
    Moreno, Carolina D.
    Tedeschi, Alessandra
    Szafer-Glusman, Edith
    Zhou, Cathy
    Abbazio, Chris
    Dean, James P.
    Szoke, Anita
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD-) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.
    Fischer, Kirsten
    Al-Sawaf, Othman
    Bahlo, Jasmin
    Fink, Anna-Maria
    Tandon, Maneesh
    Dixon, Mark
    Robrecht, Sandra
    Humphrey, Kathryn
    Boettcher, Sebastian
    Tausch, Eugen
    Humerickhouse, Rod
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Langerak, Anton W.
    Kreuzer, Karl-Anton
    Goede, Valentin
    Stilgenbauer, Stephan
    Mobasher, Mehrdad
    Ritgen, Matthias
    Hallek, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial
    Riecke, Armin
    Tausch, Eugen
    Yosifov, Deyan Y.
    Schneider, Christof
    Robrecht, Sandra
    Giza, Adam
    Mueller, Lothar
    Vehling-Kaiser, Ursula
    Eckart, Michael J.
    Freier, Werner
    Schoettker, Bjorn
    Gaska, Tobias
    Reiser, Marcel
    Fink, Anna-Maria
    Eichhorst, Barbara F.
    Fischer, Kirsten
    Hallek, Michael
    Langerbeins, Petra
    Stilgenbauer, Stephan
    BLOOD, 2023, 142
  • [26] Fixed-Duration Venetoclax-Obinutuzumab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: Follow-Up of Efficacy and Safety Results From the Multicenter, Open-Label, Randomized, Phase III CLL14 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 11 - 11
  • [27] Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study
    Mitra, Debanjali
    Trask, Peter C.
    Iyer, Shrividya
    Candrilli, Sean D.
    Kaye, James A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 95 (03) : 263 - 273
  • [28] Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study
    Debanjali Mitra
    Peter C. Trask
    Shrividya Iyer
    Sean D. Candrilli
    James A. Kaye
    International Journal of Hematology, 2012, 95 : 263 - 273
  • [29] Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study
    Boeri, Marco
    Saure, Daniel
    Schuster, Christopher
    Hill, Julie
    Guerreiro, Mariana
    Klein, Kathleen
    Hauber, Brett
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1598 - 1605
  • [30] Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study
    Roeker, Lindsey E.
    Woyach, Jennifer A.
    Cheah, Chan Y.
    Coombs, Catherine C.
    Shah, Nirav N.
    Wierda, William G.
    Patel, Manish
    Tsai, Donald E.
    Nair, Binoj
    Wang, Chunxiao
    Zhao, Xiang
    Marella, Narasimha
    Ho, Caleb
    McNeely, Samuel
    Brown, Jennifer R.
    BLOOD, 2023, 142
1234